PannTheraPi has filed a regulatory submission to initiate a Phase 2a trial for its drug candidate PTI5803, targeting focal cortical dysplasia (FCD), a rare and severe form of drug-resistant epilepsy. This oral small molecule aims to address significant unmet medical needs in both adults and children suffering from this condition, which currently has limited treatment options. The trial will assess the safety, tolerability, pharmacological profile, and initial efficacy signals of PTI5803, marking a critical step in its clinical development.

The significance of this trial lies in the potential of PTI5803 to provide a therapeutic solution for patients with FCD, a condition that has long been overlooked in terms of effective treatment options. Dr. Gilles Huberfeld, a neurologist-epileptologist and co-founder of PannTheraPi, emphasized that this submission represents a vital milestone, bringing the company closer to offering much-needed therapies. Additionally, PannTheraPi has secured a European patent for PTI5803’s use in epilepsy, complementing previously granted patents in the U.S., Canada, and Japan, thus ensuring intellectual property protection until 2037.

The appointment of Sophie Binay as General Manager and Chief Scientific Officer is another pivotal development for PannTheraPi. With 20 years of experience in advancing R&D programs, her leadership is expected to accelerate the company’s clinical strategy and operational growth. This combination of entering Phase 2a trials and strengthening leadership underscores a strategic shift that may enhance PannTheraPi’s position in the competitive landscape of neurological therapies, potentially influencing timelines for drug development in this therapeutic area.

Source: globenewswire.com